Combined left atrial appendage closure and ablation in a patient with hemophilia B, paroxysmal atrial fibrillation, and transient ischemic attack.
作者信息
Bhatti Zabeer, Goldbarg Seth
机构信息
Department of Cardiology, NewYork-Presbyterian/Queens, Flushing, New York.
Department of Cardiac Electrophysiology, Weill Cornell Medical College, NewYork-Presbyterian/Queens, Flushing, New York.
出版信息
HeartRhythm Case Rep. 2019 Feb 1;5(5):266-268. doi: 10.1016/j.hrcr.2019.01.014. eCollection 2019 May.
Abstract
摘要
相似文献
1
Combined left atrial appendage closure and ablation in a patient with hemophilia B, paroxysmal atrial fibrillation, and transient ischemic attack.
HeartRhythm Case Rep. 2019 Feb 1;5(5):266-268. doi: 10.1016/j.hrcr.2019.01.014. eCollection 2019 May.
2
Left atrial catheter ablation subsequent to Watchman® left atrial appendage device implantation: a single centre experience.
Europace. 2015 Sep;17(9):1402-6. doi: 10.1093/europace/euv037. Epub 2015 May 21.
3
Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology: Final 2-Year Outcome Data of the EWOLUTION Trial Focusing on History of Stroke and Hemorrhage.
Circ Arrhythm Electrophysiol. 2019 Apr;12(4):e006841. doi: 10.1161/CIRCEP.118.006841.
4
Catheter Ablation for Atrial Fibrillation in Patients With Watchman Left Atrial Appendage Occlusion Device: Results from a Multicenter Registry.
J Cardiovasc Electrophysiol. 2017 Feb;28(2):139-146. doi: 10.1111/jce.13148. Epub 2017 Jan 19.
5
Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN.
JACC Cardiovasc Interv. 2019 Jun 10;12(11):1055-1063. doi: 10.1016/j.jcin.2019.04.004.
6
Feasibility and clinical efficacy of left atrial ablation for the treatment of atrial tachyarrhythmias in patients with left atrial appendage closure devices.
Heart Rhythm. 2015 Jul;12(7):1524-31. doi: 10.1016/j.hrthm.2015.03.011. Epub 2015 Mar 10.
7
Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes.
Circulation. 2018 Aug 28;138(9):874-885. doi: 10.1161/CIRCULATIONAHA.118.035090.
8
5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
J Am Coll Cardiol. 2017 Dec 19;70(24):2964-2975. doi: 10.1016/j.jacc.2017.10.021. Epub 2017 Nov 4.
9
Combined catheter ablation for atrial fibrillation and Watchman® left atrial appendage occlusion procedures: Five-year experience.
J Arrhythm. 2016 Apr;32(2):119-26. doi: 10.1016/j.joa.2015.11.001. Epub 2015 Dec 8.
10
Left atrial catheter ablation in patients with previously implanted left atrial appendage closure devices.
Europace. 2019 Mar 1;21(3):428-433. doi: 10.1093/europace/euy237.
引用本文的文献
1
Percutaneous Left Atrial Appendage Closure in a Patient With Acquired Von Willebrand Disease and Atrial Fibrillation.
Cureus. 2024 Jul 6;16(7):e63936. doi: 10.7759/cureus.63936. eCollection 2024 Jul.
2
Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance.
Hemasphere. 2023 Jun 5;7(6):e900. doi: 10.1097/HS9.0000000000000900. eCollection 2023 Jun.
3
Current Therapeutic Approach to Atrial Fibrillation in Patients with Congenital Hemophilia.
J Pers Med. 2022 Mar 23;12(4):519. doi: 10.3390/jpm12040519.
4
Percutaneous left atrial appendage closure in patients with primary hemostasis disorders and atrial fibrillation.
J Interv Card Electrophysiol. 2022 Aug;64(2):497-509. doi: 10.1007/s10840-021-01073-0. Epub 2021 Nov 25.
5
Apixaban and eftrenonacog alfa treatment in a patient with moderate hemophilia B and cardiovascular disease.
Hematol Rep. 2021 Sep 24;13(3):9169. doi: 10.4081/hr.2021.9169. eCollection 2021 Sep 6.
6
Challenges of left atrial appendage closure device and anticoagulation in a patient with immune thrombocytopenia (ITP).
BMJ Case Rep. 2021 Mar 25;14(3):e241985. doi: 10.1136/bcr-2021-241985.
7
Left atrial appendage closure: a balanced management of the thromboembolic risk in patients with hemophilia and atrial fibrillation.
J Thromb Thrombolysis. 2020 Oct;50(3):668-673. doi: 10.1007/s11239-020-02097-5.
本文引用的文献
1
5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
J Am Coll Cardiol. 2017 Dec 19;70(24):2964-2975. doi: 10.1016/j.jacc.2017.10.021. Epub 2017 Nov 4.
2
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.
Heart Rhythm. 2017 Oct;14(10):e275-e444. doi: 10.1016/j.hrthm.2017.05.012. Epub 2017 May 12.
3
Patients with hemophilia: Unique challenges for atrial fibrillation management.
HeartRhythm Case Rep. 2015 Sep 3;1(6):445-448. doi: 10.1016/j.hrcr.2015.06.007. eCollection 2015 Nov.
4
Embolization of Watchman Device Following a Hybrid Radiofrequency Ablation of Atrial Fibrillation and Watchman Implantation Procedure.
J Cardiovasc Electrophysiol. 2017 Jul;28(7):835-836. doi: 10.1111/jce.13201. Epub 2017 Apr 17.
5
Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation.
J Am Heart Assoc. 2015 Nov 5;4(11):e002597. doi: 10.1161/JAHA.115.002597.
6
Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.
JAMA. 2014 Nov 19;312(19):1988-98. doi: 10.1001/jama.2014.15192.
7
Management of thromboembolic risk in persons with haemophilia and atrial fibrillation: is left atrial appendage occlusion the answer for those at high risk?
Haemophilia. 2013 Mar;19(2):e84-6. doi: 10.1111/hae.12055. Epub 2012 Dec 12.
8
Co-morbidities and quality of life in elderly persons with haemophilia.
Br J Haematol. 2010 Feb;148(4):522-33. doi: 10.1111/j.1365-2141.2009.08005.x. Epub 2009 Dec 1.
9
Deep venous thrombosis in hemophilia A.
Am J Med. 1992 Dec;93(6):699-700. doi: 10.1016/0002-9343(92)90206-q.
Zotero 插件